3b Blackbio Dx Ltd vs Global Longlife Hospital And Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of 3B Blackbio DX Ltd is ₹ 1332 as of 23 Oct 15:30 . The P/E Ratio of 3B Blackbio DX Ltd changed from 1.9 on March 2021 to 29 on March 2025 . This represents a CAGR of 72.48% over 5 yearsThe P/E Ratio of Global Longlife Hospital and Research Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of 3B Blackbio DX Ltd changed from ₹ 213.76 crore on March 2021 to ₹ 1387 crore on March 2025 . This represents a CAGR of 45.37% over 5 yearsThe Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of 3B Blackbio DX Ltd for the Jun '26 is ₹ 39.63 crore as compare to the Mar '26 revenue of ₹ 45.58 crore. This represent the decline of -13.05% The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of 3B Blackbio DX Ltd for the Jun '26 is ₹ 14.67 crore as compare to the Mar '26 ebitda of ₹ 18.64 crore. This represent the decline of -21.3% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of 3B Blackbio DX Ltd changed from ₹ 11.3 crore to ₹ 8.98 crore over 9 quarters. This represents a CAGR of -9.71% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of 3B Blackbio DX Ltd changed from 391.92 % on March 2021 to 8.69 % on March 2026 . This represents a CAGR of -47.00% over 6 yearsThe Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About 3B Blackbio DX Ltd

3D Blackbio DX Limited, formerly known as Kilpest India Limited was incorporated on May 25, 1972 as one of India's leading agro-business companies.
Thereafter, the holding Company, Kilpest India Limited got merged with 3B BlackBio Biotech India Limited and as per the Scheme of Amalgamation, the name of the Company was changed from Kilpest India Limited to 3B BlackBio DX Limited in August, 2023. The Company is a leading Indian biotech firm focused on molecular diagnostics (PCR kits, enzymes, reagents for diseases like cancer/ infectious diseases) under the 'TRUPCR' brand, alongside developing Next-Gen Sequencing (NGS) assays (TRUNGS) & Rapid Tests (TRURAPID), while continuing its traditional agrochemicals business (pesticides, bio-products), serving both labs and government sectors, driven by R&D for innovative solutions.

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution in Ahmedabad.
Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

FAQs for the comparison of 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd

Which company has a larger market capitalization, 3B Blackbio DX Ltd or Global Longlife Hospital and Research Ltd?

Market cap of 3B Blackbio DX Ltd is 1,144 Cr while Market cap of Global Longlife Hospital and Research Ltd is 13 Cr

What are the key factors driving the stock performance of 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd?

The stock performance of 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd?

As of October 25, 2026, the 3B Blackbio DX Ltd stock price is INR ₹1332.95. On the other hand, Global Longlife Hospital and Research Ltd stock price is INR ₹12.57.

How do dividend payouts of 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd compare?

To compare the dividend payouts of 3B Blackbio DX Ltd and Global Longlife Hospital and Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.